Pharma Galenica grows as promised in 2025 and breaks the 4 billion mark
Galenica met its own sales target in the past financial year. At the same time, the healthcare company confirmed its EBIT forecast.
22.01.2026, 07:08
SDA
At Group level, Galenica generated sales of CHF 4.14 billion in the past financial year, an increase of 5.5 percent, as detailed in a press release issued on Thursday. The company thus met its own target of increasing sales by between 4 and 6 percent. This is also the highest level of turnover in the company's history.
The Group has met analysts' expectations exactly. On average, they had assumed an increase in sales to 4.14 billion.
As Galenica writes, growth was broad-based and all Business sectors contributed to this. The company was able to further consolidate its position in both the pharmacy and wholesale business. The new "Diagnostics" business sector also contributed to sales growth, according to the statement.
Strong demand for prescription medicines
Sales growth was driven in particular by high demand for prescription medicines, including GLP-1-based weight loss products and dietary supplements.
The Logistics and IT division contributed revenue of 3.33 billion to total turnover, an increase of 4.8 percent. This Business sector develops and operates the logistics, IT and digital infrastructure and platforms for the entire Galenica Group as well as for customers and partners in the healthcare market.
The second Business sector, Products & Care, generated sales of CHF 1.82 billion (+6.8%). The segment develops and markets healthcare services and products via various channels such as pharmacies, online or at home to private customers and patients as well as to business customers and partners.
The acquired diagnostics service provider Labor Team is now also part of the Products & Diagnostics Business sector, where it is managed as the independent "Galenica Diagnostics" Business sector.
In terms of profit development, the Group continues to expect an increase in operating profit (EBIT) of 10 to 12 percent. It is also aiming to pay out a dividend at least on a par with the previous year (previous year: CHF 2.30 per share).
